MapLight Therapeutics Inc. 宣布,其每日一次(QD)330/6毫克剂量的治疗方案,在主要终点指标上未能实现统计学显著性。这一结果意味着该剂量方案在该项研究中并未展现出预期的疗效优势。
MapLight Therapeutics Inc. 宣布,其每日一次(QD)330/6毫克剂量的治疗方案,在主要终点指标上未能实现统计学显著性。这一结果意味着该剂量方案在该项研究中并未展现出预期的疗效优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.